Paul McEwan – Startup Investor Profile

Paul McEwan, with over 25 years of experience, has a strong background in the life science tools space and is a co-founder of companies like Agencourt Bioscience and Kapa Biosystems. He has made 20+ investments in life science start-ups, including Watchmaker Genomics and DNA Script. Paul’s investment focus areas are in life science tools and start-ups. He has a track record of successful exits with combined exit values of $700M from his co-founded companies. His investments range in life science start-ups, and he has a CEO approval rating of 83/100, placing him in the Top 10% of similarly-sized companies. With a background in project and contract management at IBM and Shell, Paul’s partnership and collaboration style emphasizes effective communication, leadership, and achieving targets. His investment check size varies based on the company and opportunity.

Location:

Country: United States of America

Investment Regions:

Investment Stages: pre-seed, seed

Website:

AI Reasoning: Search results show Paul McEwan appointed to board roles and mentioned in press releases dated Dec 4, 2024 and Apr 28, 2025 (CS Genetics). The April 28, 2025 article indicates recent activity within 6 months from the reference date; it mentions involvement with companies including Watchmaker Genomics and DNA Script. The most recent confirmed public activity is Apr 28, 2025, which is less than 6 months prior to the reference date, so classify as very-active.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.